medigraphic.com
ISSN 2796-9711 (Print)
Publicación de la Asociación Salud, Ciencia y Tecnología

2022, Number 1

<< Back Next >>

salud ciencia tec 2022; 2 (1)

Insulin resistance as a triggering factor of dyslipidemia

Pérez FRA, Pacha JAG

Language: Spanish
References: 34
Page:
PDF size: 187.85 Kb.


ABSTRACT

Insulin resistance (IR) is defined as a pathological state that is characterized by a decrease in the sensitivity of insulin in the tissues, on the other hand, dyslipidemia is a lipid level alteration that could develop from insulin resistance. This bibliographic review describes the main scientific contributions that demonstrate whether insulin resistance is one of the essential pathological conditions for developing some of the diseases that constitute serious public health problems, such as dyslipidemia, type 2 diabetes mellitus (DM2) and metabolic syndrome (MS).


REFERENCES

  1. Lozano ES. Resistencia a Insulina: Revisión de literatura. Revista Médica Hondureña 2022;90:63-70. https://doi.org/10.5377/rmh.v90i1.13824.

  2. Terlemez S, Bozdemir E, Uçar SK, Kabaroğlu C, Habif S, Kayıkçıoğlu M, et al. Insulin resistance in children with familial hyperlipidemia. Journal of Pediatric Endocrinology and Metabolism 2018;31:1349-54. https://doi.org/10.1515/jpem-2018-0337.

  3. Su X, Chen X, Wang B. Pathology of metabolically-related dyslipidemia. Clinica Chimica Acta 2021;521:107-15. https://doi.org/10.1016/j.cca.2021.06.029.

  4. Mujica FG. Insulina. Estructura, síntesis, secreción, depuración y degradación (Revisión). Vitae: Academia Biomédica Digital 2017:1.

  5. Elías-López D, Ferreira-Hermosillo A. Insulina en poblaciones especiales: resistencia a la insulina, obesidad, embarazo, adultos mayores y enfermedad renal crónica. Revista Mexicana de Endocrinología, Metabolismo & Nutrición 2021;8:59-71. https://doi.org/10.24875/RME.M21000013.

  6. Hiriart-Urdanivia M, Sánchez-Soto C, Velasco M, Sabido-Barrera J, Ortiz-Huidobro RI. El receptor soluble de insulina y el síndrome metabólico. Gac Med Mex 2019;155:541-5.

  7. Posner BI. Insulin Signalling: The Inside Story. Canadian Journal of Diabetes 2017;41:108-13. https://doi.org/10.1016/j.jcjd.2016.07.002.

  8. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 2018;19:31-44. https://doi.org/10.1038/nrm.2017.89.

  9. Valero Ávila PV, Sánchez-Pérez AM. Análisis de la expresión y función de los sustratos del receptor de insulina. Agora Salud 2020;7:297-305. https://doi.org/10.6035/AgoraSalut.2020.7.30.

  10. Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients 2020;12:1305. https://doi.org/10.3390/nu12051305.

  11. Boucher J, Kleinridders A, Kahn CR. Insulin Receptor Signaling in Normal and Insulin-Resistant States. Cold Spring Harb Perspect Biol 2014;6:a009191. https://doi.org/10.1101/cshperspect.a009191.

  12. Gutiérrez-Rodelo C, Roura-Guiberna A, Olivares-Reyes JA. Mecanismos Moleculares de la Resistencia a la Insulina: Una Actualización. Gac Med Mex 2017;153:214-28.

  13. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovascular Diabetology 2018;17:122. https://doi.org/10.1186/s12933-018-0762-4.

  14. Carter S, Hartman Y, Holder S, Thijssen DH, Hopkins ND. Sedentary Behavior and Cardiovascular Disease Risk: Mediating Mechanisms. Exercise and Sport Sciences Reviews 2017;45:80. https://doi.org/10.1249/JES.0000000000000106.

  15. Quesada MY, Hernández JC, Rode EC, Hernández OG, Bouza RC, Quesada MÁY. Índice glucosa-triglicéridos como marcador de resistencia a la insulina en pacientes con diagnóstico de hipertensión arterial esencial. Rev cubana med 2020;59:1-11.

  16. Freeman AM, Pennings N. Insulin Resistance. StatPearls, Treasure Island (FL): StatPearls Publishing; 2022.

  17. Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A. Indirect insulin resistance detection: Current clinical trends and laboratory limitations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2019;163:187-99. https://doi.org/10.5507/bp.2019.021.

  18. Mirzaalian Y, Nourian M, Gholamalizadeh M, Doaei S, Hatami M, Hassanzadeh A, et al. The association of quantitative insulin sensitivity indices (HOMA-IR and QUICKI) with anthropometric and cardiometabolic indicators in adolescents. Arch Med Sci Atheroscler Dis 2019;4:e32-7. https://doi.org/10.5114/amsad.2019.84411.

  19. Ruiz-Montero PJ, González-Fernández FT, Mikalacki M, Martín-Moya R. The use of anthropometrical variables for detection of homeostatic measurement assessment-insulin resistance (HOMA-IR) in female participants of a physical exercise program. Bratisl Lek Listy 2021;122:727-31. https://doi.org/10.4149/BLL_2021_116.

  20. Kopin L, Lowenstein CJ. Dyslipidemia. Ann Intern Med 2017;167:ITC81-96. https://doi.org/10.7326/AITC201712050.

  21. Iqbal J, Qarni AA, Hawwari A, Alghanem AF, Ahmed G. Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism. Current Diabetes Reviews s. f.;14:427-33. https://doi.org/10.2174/1573399813666170705161039.

  22. Real JT, Ascaso JF. Metabolismo lipídico y clasificación de las hiperlipemias. Clínica e Investigación en Arteriosclerosis 2021;33:3-9. https://doi.org/10.1016/j.arteri.2020.12.008.

  23. Coniglio RI. Apolipoproteína B: sus ventajas en el manejo del riesgo cardiovascular aterosclerótico. Acta bioquímica clínica latinoamericana 2021;55:11-20.

  24. Carvajal Carvajal C. Los triglicéridos y la aterogénesis. Medicina Legal de Costa Rica 2017;34:82-9.

  25. Candás Estébanez B, Pocoví Mieras M, Romero Román C, Vella Ramírez JC, Esteban Salán M, Castro Castro MJ, et al. Estrategia para el diagnóstico de las dislipidemias. Recomendación 2018. Laboratorio Clinico 2019;12:e21-33. https://doi.org/10.1016/j.labcli.2019.03.001.

  26. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. International Journal of Molecular Sciences 2022;23:786. https://doi.org/10.3390/ijms23020786.

  27. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic Advances in Cardiovascular Disease 2017;11:215-25. https://doi.org/10.1177/1753944717711379.

  28. Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocrine Reviews 2022;43:611-53. https://doi.org/10.1210/endrev/bnab037.

  29. Ramírez JP, Leo IB, González JS, Huamán HA, Cuadros MM, Henostroza OC, et al. Obesidad, resistencia a la insulina y diabetes mellitus tipo 2 en adolescentes. Anales de la Facultad de Medicina 2018;79:200-5. https://doi.org/10.15381/anales.v79i3.15311.

  30. Erol M, Bostan Gayret Ö, Hamilçıkan Ş, Can E, Yiğit ÖL. Vitamin D deficiency and insulin resistance as risk factors for dyslipidemia in obese children. Arch Argent Pediatr 2017;115:133-9. https://doi.org/10.5546/aap.2017.eng.133.

  31. Castillo Núñez Y, Aguilar Salinas CA. Nutrición en diabetes con dislipidemia. Revista de la ALAD Asociación Latinoamericana de Diabetes 2017;7:31-9.

  32. Feria Díaz GE, Leyva Proenza CA, Rodríguez Reyes ER, Rodríguez Moldón Y, Rodríguez Duque R, Feria Díaz GE, et al. Dislipidemia en estados de resistencia a la insulina. Correo Científico Médico 2019;23:1347-73.

  33. Barbosa VS do N, Gomes LS, Palma DCA. Dislipidemia em pacientes com Diabetes tipo 2. Saúde e Pesquisa 2017;10:579-85. https://doi.org/10.17765/1983-1870.2017v10n3p579-585.

  34. Cuevas M. A, Alonso K R. Dislipidemia diabética. Revista Médica Clínica Las Condes 2016;27:152-9. https://doi.org/10.1016/j.rmclc.2016.04.004.




2020     |     www.medigraphic.com